Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer by Yunxia, Zuo et al.
RESEARCH ARTICLE Open Access
Mutations in epidermal growth factor receptor
and K-ras in Chinese patients with colorectal
cancer
Zuo Yunxia
1†, Cao Jun
1†, Zhu Guanshan
2, Lu Yachao
2, Zhou Xueke
1, Li Jin
1*
Abstract
Background: Mutations of EGFR and K-ras are biomarkers for predicting the efficacy of targeting agents in non-
small-cell lung cancer (NSCLC) and colorectal cancer (CRC). Data on the gene mutation status of EGFR and K-ras in
Chinese patients with CRC are limited.
Methods: EGFR mutations in exon 18-21 and K-ras mutations in exon 1 and 2 were detected in tumor samples
from 101 Chinese patients with CRC by polymerase chain reaction-single strand conformational polymorphism. The
relationship between patients’ characteristics and survival time and gene mutation status were analyzed using the
Statistical Package for the Social Sciences.
Results: Only two samples (2.0%) had EGFR mutations in exon 18 or 21, and 33 of 101 samples (32.7%) had K-ras
mutations in codon 12, 13, 45, 69, or 80. Univariate analysis suggested that differentiation might be correlated with
K-ras mutations (p = 0.05), which was confirmed by a logistic regression model (p = 0.04). The median overall
survival (OS) and median survival after metastasis were 44.0 and 18.0 months, respectively, in the mutant K-ras
group, and 53.3 and 19.0 months, respectively, in the wild K-ras group. K-ras mutation was not an independent
prognostic factor for OS or survival after metastasis (p = 0.79 and 0.78, respectively).
Conclusions: In Chinese patients with CRC, EGFR mutations were rare, and K-ras mutations were similar to those
of Europeans. New mutations in codons 45, 69, and 80 were found in the Chinese population. Poor differentiation
was an independent factor related to K-ras mutations.
Background
Epidermal growth factor receptor (EGFR) is highly
expressed in many malignancies, including head and
neck cancer, lung cancer, and colorectal cancer[1].
Upregulated EGFR is correlated with both poor prog-
nosis and increased metastatic potential in numerous
epithelial malignancies[2,3]. Further investigation has
recently revealed that, in patients with non-small cell
lung cancer (NSCLC) with mutated EGFR, higher
response rates and longer survival time could be
achieved with the use of the EGFR tyrosine kinase inhi-
bitor gefitinib. The mutations were centered on exon
18-21 of the EGFR tyrosine kinase domain and were
mostly detected in Asian patients with NSCLC, which
suggested that gefitinib played an important role in the
Chinese population[4,5]. It has been reported that the
mutation incidence in colorectal cancer (CRC) was
approximately 0.34% to 3.00% in western countries [6,7].
In contrast, the mutation incidence was reported to be
as high as 12% in a study from Japan of 33 patients with
CRC[8]. However, the differences between Western and
Eastern patients with CRC have not been clearly docu-
mented, and no data from Chinese patients with CRC
are currently available.
The K-ras gene is located downstream in the EGFR
signal pathway. The Ras protein is activated transiently
as a response to extracellular signals, such as growth
factors, cytokines, and hormones that stimulate cell
surface receptors. It can switch between an inactive
state, in which the proteins are bound to guanosine-
diphosphates, and an active state, in which conversion
to guanosine-triphosphate (GTP) occurs. Mutant
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any medium, provided the original work is properly cited.activated forms of Ras proteins have an impaired intrin-
sic GTPase activity, which renders the protein resistant
to inactivation by regulatory GTPase-activating proteins
[9]. Approximately 20% to 50% of patients with colorec-
tal adenocarcinoma have a K-ras mutation, and 90% of
the mutations were found in codons 12 and 13, followed
by codon 61[10]. Studies have recently confirmed that a
mutant K-ras gene could lead to resistance to cetuximab
and panitumumab in metastatic CRC (mCRC), suggest-
ing that K-ras status should be considered when select-
ing patients with mCRC as candidates for panitumumab
or cetuximab monotherapy[11,12].
Mutations in both EGFR and K-ras will promote the
progression of resistance to anti-EGFR targeting therapy.
Limited data in the Chinese population prompted this
study, which was performed to explore mutations in
EGFR and K-ras gene in Chinese patients with CRC and
provide evidence for the efficacy-prediction of EGFR tar-
geting therapeutic strategies.
Methods
Tissue samples
Study approval was provided by the Medical Ethical
Committees of the Fudan University Cancer Hospital,
Shanghai, China, a specialist cancer hospital serving
mainland China (60% of patients attend from other
provinces, many of whom have late-stage disease). All
samples of colorectal adenocarcinoma from opera-
tions performed at the Fudan University Cancer Hos-
pital between January 2004 and March 2006, for
which full information was available, were included.
101 samples that fit the inclusion criteria were
obtained. The slides were first selected under the
microscope to ensure that it contained sufficient
tumor material. The paraffin-embedded tumor tissue
blocks were then dissected into 8-10 μm sections for
PCR sample preparation.
DNA extraction
First, 200-μLc e l ll y s i ss o l u t i o na n d2 0 - μlp r o t e i n a s eK
stock solution were added to the tissue samples and
incubated for 1 hour at 60°C, then for 20 minutes at
70°C. Subsequently, DNA was extracted after 72 hours
at 37°C, protein was removed, and the DNA was preci-
pitated using 100% 2-propanol and dissolved in hydration
buffer.
Polymerase chain reaction amplification and product
purification
Four fragments of exon 18-21 of the EGFR gene and
two fragments of exon 1 and 2, which included K-ras
codons 12, 13, and 61, were amplified from isolated
genomic DNA using polymerase chain reaction (PCR).
Primer
Primers of the EGFR exon 18-21 were as follows:
First reaction of exon 18: 5’ GAC CCT TGT CTC
TGT GTT CTT GT 3’,5 ’ C T TT G GT C TG T GA A T
TGG TCT C 3’;
Second reaction of exon 18: 5’ TGA GGA TCT TGA
AGG AAA CTG AAT 3’,5 ’TGC CA G GGA CCT TAC
CTT ATA CA 3’;
First reaction of exon 19: 5’ CCC CAG CAA TAT
CAG CCT TAG 3’,5 ’ TGA AGT TTT AGG ATG TGG
AGA TGA 3’;
Second reaction of exon 19: 5’GTG CAT CGC TGG
TAA CAT CCA C 3’,5’ CAG AGC AGC TGC CAG
ACA TGA G 3’;
First reaction of exon 20: 5’ TCC ACA TCC TAA
AAC TTC ACA GC 3’,5 ’ GCA GAC CGC ATG TGA
GGA TC 3’.
Second reaction of exon 20: 5’ CCA TGA GTA CGT
ATT TTG AAA CTC 3’,5 ’ TTA TCT CCC CTC CCC
GTA TC 3’;
First reaction of exon 21: 5’ CTA ACG TTC GCC
AGC CAT AAG TCC 3’,5 ’ GCT GCG AGC TCA CCC
AGA ATG TCT GG 3’; and
Second reaction of exon 21: 5’ CTG AAT TCG GAT
GCA GAG CTT C 3’,5 ’ GAG AGC ATC CTC CCC
TGC ATG TG 3’.
P r i m e r so ft h et w of r a g m e n t so fK - r a se x o n1a n d2
were as follows:
First reaction of exon 1: 5’ TCT TAA GCG TCG
ATG GAG GAG 3’,5 ’ TGA CAT ACT CCC AAG
GAA AGT AAA G 3’;
Second reaction of exon 1: 5’ ATA CAC GTC TGC
AGT CAA CTG G 3’,5 ’ CCT CTA TTG TTG GAT
CAT ATT CGT 3’;
First reaction of exon 2: 5’ ATG GGT ATG TGG
TAG CAT CTC AT 3’,5 ’ AAG TTA CTC CAC TGC
TCT AAT CCC 3’;
Second reaction of exon 2: 5 ‘TTT TCC TGA CTA
TTG ATG ATG TTG 3’,
5’ GCA TGG CAT TAG CAA AGA CTC 3’.
The PCR cycling variables are listed below:
EGFR exon 18
One cycle at 96°C for 5 minutes, 10 cycles each at
95°C for 10 seconds, 57°C for 45 seconds, and 72°C for
25 seconds (0.5°C descended at each cycle), 40 cycles
each at 95°C for 20 seconds, 52°C for 30 seconds, and
72°C for 30 seconds, followed by one cycle at 72°C for 5
minutes.
EGFR exon 19 and exon 21
One cycle at 95°C for 5 minutes, 20 cycles each at 94°C
for 20 seconds, 58°C for 45 seconds, and 72°C for 25
seconds (0.5°C descended at each cycle), 35 cycles each
at 95°C for 20 seconds, 48°C for 30 seconds, and 72°C
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minutes.
EGFR exon 20
One cycle at 96°C for 5 minutes, 10 cycles each at 95°C
for 10 seconds, 60°C for 30 seconds, and 72°C for 20 sec-
onds (0.5°C descended at each cycle), 40 cycles each at
95°C for 20 seconds, 55°C for 30 seconds, and 72°C for
30 seconds, followed by one cycle at 72°C for 4 minutes.
K-ras exon 1 and exon 2
One cycle at 95°C for 5 minutes, 20 cycles each at 94°C
for 20 seconds, 58°C for 45 seconds, and 72°C for 25 sec-
onds (0.5°C descended at each cycle), 30 cycles each at
95°C for 20 seconds, 48°C for 30 seconds, and 72°C for
25 seconds, followed by one cycle at 72°C for 3 minutes.
The same cycling conditions were used for both exter-
nal and internal primers.
The internal products were checked for purity and
size by electrophoresis on a 2% agarose gel and subse-
quently used for direct sequencing.
Mutation analysis
The resulting PCR products were sequenced using the
Big Dye Terminator Cycle Sequence Ready Reaction Kit
(Applied Biosystems, Foster City, CA, USA) following
the manufacturer’s protocol. The EGFR and K-ras
sequences were aligned and analyzed with the Sequen-
cing Analysis v5.1 software.
Survival
Overall survival (OS) was defined from the day of opera-
tion to the day the patient died of the disease or the day
follow-up ended (August 2008). Survival after metastasis
was defined from the day metastasis was confirmed to the
day the patient died of the disease or the day follow-up
ended (August 2008). Follow-up was done by telephone.
Statistical analysis
Differences in mean values were evaluated using t-test.
Differences in categorical variables, such as sex, age, and
tumor sub-localization, between patients with and with-
out K-ras mutations were evaluated for significance with
chi-squared test (or Fisher’s exact test when necessary).
Multivariate analysis was done with a logistic regression
model. Kaplan-Meier method and log-rank tests were
used for univariate survival analysis, and a Cox regres-
sion model was used in multivariate survival analysis.
A p value of ≤0.05 was considered statistically signifi-
cant. Statistical analyses were performed using the
Statistical Package for the Social Sciences version 12.0.
Results
Patients’ Characteristics
No significant differences in age were found between the
59 male patients and 42 female patients (57.3 years vs.
54.8 years, respectively, p =0 . 3 3 1 ,t-test). Other charac-
teristics, such as tumor sub-localization, pathology, dif-
ferentiation, and International Union Against Cancer
(UICC) stage, are listed in Table 1.
Epidermal growth factor receptor and K-ras gene
mutation types
Only 2 of 101 samples (2.0%) were found with muta-
tions in exon 18 or 21 of the EGFR gene; both of which
were substitutions and heterozygous and missense
mutations. The mutation in one sample was 2183A>G
in exon 18, leading to substitution of a glutamine by
leucine acid (Gln849Leu). The other sample had two
mutations of 2546A>T and 2611G>A both in exon 21,
leading to transitions of Lys728Arg and Ala871Thr,
respectively. No mutations were detected either in exons
19 or 20 (Table 2 and Fig 1).
In exon 1 and 2 of the K-ras gene, 34 mutations were
found in 33 of 101 samples (32.7%); all of which were
substitutions and missense mutations. Thirty of 34
mutations (88.2%) were found in codon 12. The most
frequently observed mutations were heterozygous
35G>A transitions (16/34 mutations) and heterozygous
34 G>T transitions (6/34 mutations) in codon 12, lead-
ing to transitions of Gly12Asp and Gly12Cys, respec-
tively. Other mutations inc o d o n1 2i n c l u d e dt h r e e
heterozygous 34G>A (Gly12Ser), one homozygous
35G>A (Gly12Asp), one heterozygous 35G>C
Table 1 Patients’ characteristics.
Number (%)
Number of patients 101 (100)
Sex
Male 59 (58.4)
Female 42 (41.6)
Sub-localization
Colon 54 (53.5)
Rectum 47 (46.5)
Adenocarcinoma
Tubular/papillary 32 (31.7)
Mucinous 12 (11.9)
Others 57 (56.4)
Differentiation
Good 2 (2.0)
Moderate 69 (68.3)
Poor 11 (10.9)
Unknown 19 (18.8)
Stage (UICC
a)
I 7 (6.9)
II 20 (19.8)
III 49 (48.5)
IV 25 (24.8)
aInternational Union Against Cancer.
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Page 3 of 10(Gly12Ala), one heterozygous 35G>T (Gly12Val), one
homozygous 34G>T (Gly12Cys), and one homozygous
34G>A (Gly12Ser) transitions. One sample with hetero-
zygous 35G>A transition in codon 12 was also found
with homozygous 205G>A transition in codon 69, lead-
ing to a transition of Asp69Asn. The other mutations
were one heterozygous 38 G>A (Gly13Asp) in codon 13,
one homozygous 133G>A (Val45Ile) in codon 45, and
one heterozygous 239G>A (Cys80Tyr) in codon 80
(Table 2 and Fig 1). No samples were detected with
concurrent EGFR and K-ras gene mutations.
Clinicopathological factors correlated with K-ras
mutations
Differences in the categorical variables, including sex,
age, tumor sub-localization, pathology, differentiation,
and UICC stage, between patients with and without K-
ras mutations were evaluated for significance with chi-
squared test (Fisher’s exact test when necessary). Only
the factor of differentiation was found to be potentially
correlated with K-ras mutations (p =0 . 0 5 ) ,w h i c h
showed that poorer differentiation might predict a
greater possibility of K-ras mutations (Table 3), which
was confirmed by multivariate analysis with a logistic
regression model (p = 0.04).
Univariate survival analysis on K-ras status
Median follow-up time of all the patients was 37.0
months. Median OS was 44.0 months (55 dead and 46
alive) in the whole group, 44.0 months in the K-ras
mutation subgroup, and 53.3 months for the wild K-ras
subgroup. No statistically significant difference was
detected between the two subgroups (p = 0.23) [Fig 2].
Median survival after relapse of the 66 patients with
confirmed metastasis was 18.0 months overall, 18.0
months in the K-ras mutation subgroup, and 19.0
months in the wild K-ras subgroup. No statistically sig-
nificant difference was detected between the two sub-
groups (p = 0.59) [Fig 3].
Multivariate survival analysis of K-ras status
Prognostic factors of sex, age, tumor sub-localization,
pathology, differentiation, UICC stage, and K-ras status
were analyzed using a Cox regression model. K-ras
mutation was not an independent factor that correlated
with OS or survival after metastasis (p = 0.79 and 0.78,
respectively).
Discussion
Better efficacy of the EGFR tyrosine kinase inhibitor
(EGFR-TKI) gefitinib has been documented in Asian
patients with NSCLC than in Caucasians[13]. The main
reason for this finding is somatic mutations in the
EGFR tyrosine kinase domain, which are more prevalent
in Asian patients with NSCLC. Therefore, these muta-
tions might be considered biomarkers for the use of
gefitinib in the treatment of NSCLC. However, this
study did not find similar results in Chinese patients
with CRC. In total, 101 paraffin-section from colorectal
adenocarcinoma samples were selected, and mutations
in EGFR exon 18-21 were identified. Only 2.0% of the
samples had mutations in exon 18 or 21, which was
similar to that in the Western population. Substitutions
of A2183G (Lys728Arg) in exon 18 and A2546T
(Gln849Leu) and G2611A (Ala871Thr) in exon 21 were
the only three mutations detected. No mutations were
Table 2 Epidermal growth factor receptor and K-ras mutations.
Site Wild type Type of point mutation Number of mutations (%) Amino acid Heterozygous/homozygous
EGFRa
[SME1]
Exon 18 AAG 2183A>G 1 (33.3) Gln849Leu Heterozygous
Exon 21 CAG 2546A>T 1 (33.3) Lys728Arg Heterozygous
Exon 21 GCA 2611G>A 1 (33.3) Ala871Thr Heterozygous
K-ras Codon 12 GGT 35G>A 16 (47.1) Gly12Asp Heterozygous
Codon 12 GGT 34G>T 6 (17.6) Gly12Cys Heterozygous
Codon 12 GGT 34G>A 3 (8.8) Gly12Ser Heterozygous
Codon 12 GGT 34G>A 1 (2.9) Gly12Ser Homozygous
Codon 12 GGT 34G>T 1 (2.9) Gly12Cys Homozygous
Codon 12 GGT 35G>C 1 (2.9) Gly12Ala Heterozygous
Codon 12 GGT 35G>A 1 (2.9) Gly12Asp Homozygous
Codon 12 GGT 35G>T 1 (2.9) Gly12Val Heterozygous
Codon 13 GGC 38G>A 1 (2.9) Gly13Asp Heterozygous
Codon 45 GTA 133G>A 1 (2.9) Val45Ile Homozygous
Codon 69 GAC 205G>A 1 (2.9) Asp69Asn Homozygous
Codon 80 TGT 239G>A 1 (2.9) Cys80Tyr Heterozygous
a Epidermal growth factor receptor.
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Page 5 of 10found in exon 19 or 20, which was different from the
results in NSCLC, in which the principal mutation was
a deletion in exon 19. The mutation incidence varied
among different studies. Barber et al.[6] reported a
0.34% mutation incidence of Gly719Ser in 293 CRC
samples in the USA, and Ogino et al.[7] found a 3.3%
incidence of Gly724Ser in 30 samples, while no muta-
tions were detected in Lynch et al.’s [4]study of 20 sam-
ples. However, a study from Japan reported by Nagahara
et al.[8] found a relatively higher mutation incidence of
12% (4 of 33 samples). The mutations were all substitu-
tions of Glu749Lys in exon 19 and Glu762Gly and
Ala767Thr in exon 20. This study found that EGFR
mutations were rare in Chinese patients with CRC,
which was similar to the results from Western countries,
but greatly different from those in Chinese patients with
NSCLC.
EGFR-TKIs have shown satisfactory efficacy as first-,
second-, or third-line therapy for patients with NSCLC
with EGFR mutations. Similar studies of patients with
CRC have been performed to investigate the application
of EGFR-TKIs in this setting. A phase II study showed
that two doses of gefitinib (250 mg/day and 500 mg/
day) resulted in a partial response rate of 1% (1 of 110
patients) with a median progression-free survival of 1.9
months[14]. Townsley et al.[15] treated 39 patients with
mCRC with erlotinib. Of 31 evaluable patients, 19 (61%)
had progressive disease, and 12 (39%) had stable disease.
However, there was a reduction in phosphorylated
EGFR and phospho-extracellular signal-regulated kinase
in tumor tissue after treatment. From these studies, gefi-
tinib or erlotinib monotherapy seems unlikely to be
effective for patients with CRC. The lower response rate
for mCRC could be explained by a lower incidence of
EGFR mutations than that found in NSCLC.
Further trials have focused on the combination of
TKIs and chemotherapy. In a phase II study, the combi-
nation of capecitabine, oxaliplatin, and erlotinib seemed
to have promising activity for patients who had received
prior chemotherapy with a relatively high response rate
(25%) and progression free survival (PFS) (5.4 months)
compared with previous reports of either infusional 5-
fluorouracil (5-FU), leucovorin, and oxaliplatin or cape-
citabine and oxaliplatin in a similar patient population
[16]. Oxaliplatin, leucovorin, and 5-FU (FOLFOX-4) in
combination with gefitinib in patients who failed irinote-
can as a second-line therapy achieved a response rate of
33%, which was higher than that of FOLFOX-4 alone
(10%)[17]. However, phase III trials are needed to eradi-
cate selection bias before conclusions about the efficacy
of the combination of EGFR-TKIs and chemotherapy
can be confirmed.
In total, 34 mutations (32.7%) were found in 33 sam-
ples in this study, including common mutations in
Table 3 Patients’ characteristics according to K-ras mutation status.
K-ras mutation status p Value
Mutation Number of patients Wild type Number of patients
Number of patients 33 68
Sex 0.16
Male 16 43
Female 17 25
Age (years) 0.89
≤56 17 34
>56 16 34
Sub-localization 0.26
Colon 15 39
Rectum 18 29
Adenocarcinoma 0.84
Tubular/papillary 10 22
Others 23 46
Differentiation 0.05
Good 2 0
Moderate 18 51
Poor 4 7
Unknown 9 10
Stage (UICC
a) 0.18
I + II 6 21
III + IV 27 47
aInternational Union Against Cancer.
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69, and 80. The mutation incidence and most sites of
mutation were all concordant with those reported in
previous studies[18]. However, only one mutation in
codon 13 was detected in the Chinese CRC samples,
which is less than that reported in western studies. The
three mutations found in codons 45, 69, and 80, which
have not previously been reported, suggest that, occa-
sionally, CRC in Chinese patients might have different
biologic behavior and drug resistance although it is
rarely detected. This is an exciting result because it sug-
gests the possibility that other differences between Chi-
nese and Western patients with CRC could be present,
which could help in finding new individual treatments
for Chinese patients. No mutations in codon 61 were
detected in this study. It was reported in Western stu-
dies that approximately 90% of the activating mutations
were found in codons 12 and 13 of exon 1 and ~5% in
codon 61 located in exon 2[19-21]. Similarly, the muta-
tion incidence of codon 61 was 0-4.8% in domestic
reports. Therefore, our results were concordant with
that of previous studies.
Differences in the categorical variables of sex, age,
tumor sub-localization, pathology, differentiation, and
UICC stage between patients with and without K-ras
mutations were evaluated for significance with both chi-
squared test and multivariate analyses. Only the factor
of differentiation was potentially correlated with K-ras
mutations (p = 0.05), which suggested that poor differ-
entiation might predict K-ras mutations. This correla-
tion was confirmed by multivariate analysis done with a
logistic regression model. Duke’s stage, lymph node
metastasis, special pathology, and other factors were
suggested as possible parameters related to K-ras muta-
tions in previous studies, but no correlation has been
achieved yet[22,23]. Currently, no conclusion can be
made due to the lack of a meta-analysis, but this investi-
gation will be continued with a larger sample.
Correlations between K-ras mutations and survival in
CRC have been controversial. Although a notable short-
ening of OS was noted for the K-ras mutation subgroup
compared with the wild K-ras subgroup, no statistical
significance was detected by univariate and multivariate
analysis. Similarly, no correlation was found between
Figure 2 Overall survival and K-ras status
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ate and multivariate analyses. Some investigators have
concluded that K-ras mutations could lead to poor sur-
vival, especially when anti-EGFR antibodies plus che-
motherapy[11,24] were used, while others have found
no significant correlation between K-ras mutations and
survival[25,26], which was consistent with this study.
However, some studies have shown that specific nucleo-
tide mutations, inducing amino acid mutations, might
be relevant to survival[18,27]. For example, Gly12Val
mutations in codon 12 [27] and the G>A mutation in
codon 13[18]both might induce poor survival. As only a
few mutations in codon 12 and only one in codon 13
were detected in this study, and the follow-up time was
insufficient, it was difficult to identify a definite correla-
tion between K-ras mutations and survival. A further
study with a larger sample size is ongoing, and more
encouraging results might be found.
In NSCLC, K-ras mutations are related to the resis-
tance of EGFR-TKIs, which are the opposite of EGFR
mutations[28]. Some studies have recently indicated that
K-ras mutations are responsible for the low response
rate to EGFR monoclonal antibodies[11,29]. A similar
result has been found in another large study, which
confirmed that wild-type K-ras was required for panitu-
mumab (an EGFR monoclonal antibody) efficacy in
patients with mCRC [12]. At the 2009 American Society
of Clinical Oncology Annual Meeting, there was an
encouraging report of 540 samples from the CRYSTAL
trial that were analyzed to evaluate treatment effect stra-
tified by K-ras mutation status (Rougier et al. 2009,
unpublished data). A statistically significant difference
was seen in favor of cetuximab for best overall response
(p = 0.0025), reducing the risk of progression (p =
0.0167) for patients with K-ras wild-type mutations,
while no benefit was seen from the addition of cetuxi-
mab for the K-ras mutation subgroup. These data
demonstrated that the treatment effect of cetuximab in
patients with K-ras wild-type mutations was significantly
enhanced compared with standard chemotherapy alone,
whereas patients with a K-ras mutation could not be
shown to benefit from cetuximab treatment. Therefore,
K-ras status detection is recommended before the use of
EGFR monoclonal antibodies. However, most patients
with recurrent or metastatic disease in our study were
not treated with EGFR monoclonal antibodies because
they were mostly treated between 2004 and 2007. When
cetuximab became available in 2006 in China, 13
Figure 3 Survival after relapse versus K-ras status
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Page 8 of 10patients were treated with this drug as a first- to third-
line treatment, although many patients with recurrent
or metastatic disease were not given cetuximab for
financial reasons. Prior to 2006, conventional treatment
was given. Due to the limited data on cetuximab treat-
ment, we expect more studies on the relationship
between K-ras mutations and cetuximab efficacy in the
Chinese population because cetuximab is much more
widely used in our hospital at present.
Conclusions
EGFR mutations are rare in Chinese patients with CRC,
which is similar to the results in those with NSCLC.
Therefore, gefitinib might be ineffective for CRC. K-ras
mutations were similar in Chinese patients with CRC to
that in Western populations, and substitutions in codon
12 are the most common mutations. Poor differentiation
is an independent factor related to K-ras mutation. K-
ras mutation might not be a prognostic factor but may
be a predictor of resistance to EGFR monoclonal
antibodies.
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